Business
TransCode Therapeutics Reports 2022 Results; Provides Business Update
BOSTON, March 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"BOSTON, March 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for 2022 and recent business progress. “Despite the continued turbulence in the biotech sector, 2022 was extremely productive and, we believe, successful for TransCode. The year was highlighted by FDA’s approval to proceed with our planned Phase 0, First-In-Human, clinical trial with our lead therapeutic candidate in cancer patients with advanced solid tumors,” said Michael Dudley, Co-Founder, President and CEO of TransCode. “We achieved many important milestones, advancing our pipeline of therapeutic candidates enabled by our proprietary delivery platform. We also continued to de-risk our therapeutic candidates as we march toward the clinic to treat cancer patients using a variety of RNA approaches.” TransCode’s Co-Founder and Chief Technology Officer, Dr. Zdravka Medarova, added, “We made a great deal of progress advancing all of our therapeutic candidates in 2022 and are excited to continue that progress with TTX-CRISPR, TTX-mRNA and TTX-RIGA . We are looking forward to the upcoming FIH clinical trial that we hope will advance our potential to deliver RNA therapeutics to tumors and metastases in cancer patients”. Key 2022 Highlights Received written FDA authorization to conduct our Phase 0, First-In-Human, clinical trial with TTX-MC138, our lead therapeutic candidateAnnounced strategic alliance with The University of Texas MD Anderson Cancer CenterReceived Orphan Drug Designation (ODD) for TTX-siPDL1 in pancreatic cancerAchieved positive preclinical results in pancreatic cancer with both TTX-MC138 and TTX-SiPLDL1Expanded our RNA oncology patent portfolioAppointed Dr. Frank Slack (Director of the HMS Initiative for RNA Medicine) to our scientific advisory board Recent Milestone Achievements Therapeutic Candidates TTX-MC138 Significant progress toward completion of IND-enabling studies to support filing an IND application for a Phase I/2 clinical trial with TTX-MC138Positive preclinical results with TTX-MC138 in pancreatic adenocarcinoma; 40% of animals treated with TTX-MC138 had complete responses, defined as complete regression of disease and long-term survival without recurrenceReceived second ODD from FDA, for TTX-MC138 in panc...